Method and apparatus for rapid and selective transurethral tissue ablation

Information

  • Patent Grant
  • 12161397
  • Patent Number
    12,161,397
  • Date Filed
    Thursday, January 13, 2022
    3 years ago
  • Date Issued
    Tuesday, December 10, 2024
    a month ago
Abstract
Catheter systems, tools and methods are disclosed for the selective and rapid application of DC voltage pulses to drive irreversible electroporation for minimally invasive transurethral prostate ablation. In one embodiment, a switch unit is used to modulate and apply voltage pulses from a cardiac defibrillator, while in another, the system controller can be configured to apply voltages to an independently selected multiplicity or subsets of electrodes. Devices are disclosed for more effective DC voltage application including the infusion of cooled fluid to elevate the irreversible electroporation threshold of urethral wall tissue and to selectively ablate regions of prostate tissue alone.
Description
BACKGROUND

The embodiments described herein relate generally to medical devices for therapeutic electrical energy delivery, and more particularly to the surgical specialty of urology. Specifically, systems and methods for delivering electrical energy in the context of ablating tissue rapidly and selectively in minimally invasive transurethral clinical therapies by the application of suitably timed pulsed voltages that generate irreversible electroporation of cell membranes. Such irreversible electroporation can possibly be generated in conjunction with the application of disclosed means of enhancing electroporation efficacy.


Transurethral resection of the prostate (TURP) remains the gold standard for treating benign prostatic hypertrophy (BPH). Alternatives to surgical resection are ablation of tissues using thermal-based destruction of tissue using multiple forms of energy (laser, microwave, radiofrequency ablation etc.). The most common postoperative complication with known transurethral procedures is urethral stricture, occurring in approximately 4.4% of patients overall. Furthermore known transurethral procedures indiscriminately resect or ablate urethral epithelium in the process of de-bulking the prostate tissues. The urethral injury contributes to the recovery time and morbidity of the acute procedure.


In the past decade or two the technique of electroporation has advanced from the laboratory to clinical applications, while the effects of brief pulses of high voltages and large electric fields on tissue has been investigated for the past forty years or more. It has been known that the application of brief high DC voltages to tissue, thereby generating locally high electric fields typically in the range of hundreds of Volts/centimeter can disrupt cell membranes by generating pores in the cell membrane. While the precise mechanism of this electrically-driven pore generation or electroporation is not well understood, it is thought that the application of relatively large electric fields generates instabilities in the lipid bilayers in cell membranes, causing the occurrence of a distribution of local gaps or pores in the membrane. If the applied electric field at the membrane is larger than a threshold value, the electroporation is irreversible and the pores remain open, permitting exchange of material across the membrane and leading to apoptosis or cell death. Subsequently the tissue heals in a natural process.


Historically, known direct current ablation techniques were pioneered in cardiovascular catheter-based ablation. More recently these techniques have been applied for the treatment of solid tumors with a clinical tool that employed very short impulses. The application of known ablation techniques to solid tumors on other applications, however, has not included selectively targeting tissue for irreversible electroporation ablation. Specifically, tissue susceptibility to irreversible cell injury from strong brief pulses of electricity depends on a number of important variables. Factors include: cell size, geometry, and orientation within the electric field, the constitution of the cell membrane and organelles, and local temperature. While pulsed DC voltages are known to drive electroporation under the right circumstances, the examples of electroporation applications in medicine and delivery methods described in the prior art do not discuss specificity and rapidity of action.


Thus, there is a need for selective energy delivery for electroporation and its modulation in various tissue types as well as pulses that permit rapid action and completion of therapy delivery. There is also a need for more effective generation of voltage pulses and control methods, as well as appropriate devices or tools addressing a variety of specific clinical applications, particularly in minimally invasive applications. Such more selective and effective electroporation delivery methods can broaden the areas of clinical application of electroporation including therapeutic treatment of a variety of cardiac arrhythmias, tissue ablation, and transurethral applications.


SUMMARY

The embodiments described herein address the need for tools and methods for rapid and selective application of irreversible electroporation therapy as well as pulse generation and methods in the context of transurethral applications such as in the minimally invasive treatment of benign prostate hyperplasia. In some embodiments [FILL IN]





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a schematic illustration of an irreversible electroporation system that includes a DC voltage/signal generator, a controller unit that is configurable to apply voltages to selected subsets of electrodes with independent subset selections for anode and cathode and that is connected to a computer, and one or more medical devices connected to the controller.



FIG. 1B is a schematic illustration of an irreversible electroporation system that includes a DC voltage/signal generator and a controller according to an embodiment.



FIG. 2 is a schematic illustration of a waveform generated by the irreversible electroporation system according to an embodiment, showing a balanced square wave.



FIG. 3 is a schematic illustration of a waveform generated by the irreversible electroporation system according to an embodiment, showing a balanced biphasic square wave.



FIG. 4 is a schematic illustration of a waveform generated by the irreversible electroporation system according to an embodiment, showing a progressive balanced biphasic square wave.



FIG. 5 is a schematic illustration of a distal portion of a catheter according to an embodiment, showing two distal electrodes and a lumen for transfer of fluid through the catheter.



FIG. 6 is a schematic illustration of a distal portion of a catheter according to an embodiment in a tubular anatomy, where two electrodes with the roles of cathode and anode are shown, along with a schematic depiction of the electric field in the region between the electrodes.



FIG. 7 is a schematic illustration of a distal portion of a catheter according to an embodiment, where multiple electrodes are shown with their various respective roles of anodes or cathodes, along with a schematic depiction of the electric field in the regions between the electrodes.



FIG. 8 is a schematic illustration of a distal portion of the catheter shown in FIG. 7, where multiple electrodes are shown along with simulation results for isomagnitude contours of electric field lines around the distal portion of the catheter.



FIG. 9 is an illustration of a catheter according to an embodiment with a series of lateral ablation electrodes, lateral ports for circulation of cooling fluid, and a distal balloon for holding the catheter distal tip firmly in the bladder.



FIG. 10 is an illustration of a cross section of the shaft of the catheter shown in FIG. 9, with a multiplicity of lumens for circulation of cooling fluid, draining of the bladder, electrode leads, and distal balloon inflation.



FIG. 11 is a schematic depiction of electric field lines around the cross section of a catheter according to an embodiment with a series of lateral ablation electrodes.



FIG. 12 is a schematic illustration of the cross section of a catheter according to an embodiment with a series of lateral ablation electrodes located within a urethra surrounded by prostate tissue, with cooling fluid infused from lateral ports filling an annular space in the urethra.



FIG. 13 is an illustration of a system for selective prostate tissue electroporation ablation according to an embodiment, including an ablation catheter with ports for cooling fluid infused into the urethra to maintain the urethral tissue lining at a relatively low temperature, and a trans-rectal probe inserted into the rectum and placed in apposition to the prostate and incorporating means for delivery of thermal energy to prostate tissue in order to maintain it at a relatively high temperature.



FIG. 14 is an illustration of an electroporation ablation catheter according to an embodiment, showing a series of lateral electrodes with ports incorporated for circulation of cooling fluid, and including a distal balloon and a distal tip electrode.



FIG. 15 is an illustration of an electroporation ablation catheter according to an embodiment, showing a series of ring electrodes, a series of lateral ports, and including a distal balloon and a distal tip electrode.



FIG. 16 is an illustration of an electroporation ablation catheter according to an embodiment with a series of ring electrodes, lateral ports for cooling fluid circulation and a distal tip electrode, showing a cut-away cross section view of the catheter shaft, and including a multiplicity of lumens for circulation of cooling fluid, draining of the bladder, electrode leads, and distal balloon inflation.



FIG. 17 is an illustration of an electroporation ablation catheter according to an embodiment, showing a long flexible electrode, a series of lateral ports, and including a distal balloon and a distal tip electrode.



FIG. 18 is an illustration of an electroporation ablation catheter according to an embodiment, with a long flexible electrode, lateral ports for cooling fluid circulation and a distal tip electrode, showing a cut-away cross section view of the catheter shaft, and including a multiplicity of lumens for circulation of cooling fluid, draining of the bladder, electrode leads, and distal balloon inflation.



FIG. 19 is an illustration of left and right lateral views of an electroporation ablation catheter according to an embodiment with a long flexible electrode and a series of lateral ports.



FIG. 20 is a schematic illustration of a device and electroporation system according to an embodiment for transurethral ablation with a defibrillator voltage input.



FIG. 21 is a schematic illustration of a device and electroporation system according to an embodiment for transurethral ablation with a defibrillator voltage input and a cooled fluid pump for pumping cold fluid through the device.





DETAILED DESCRIPTION

Systems and methods for electroporation to ablate enlarged prostate tissue in a selective fashion are described herein. The embodiments described herein result in well-controlled and specific delivery of electroporation in an efficacious manner. Specifically, the systems and methods described herein produced the desired results while ensuring at the same time that delicate epithelial tissue in and around the urethral wall is not damaged.


The embodiments described herein account for the differences in irreversible ablation threshold by creating a local temperature gradient that protects urethral epithelium (cooling it to raise the threshold electric field for ablation) and heating the target prostate tissue (warming it to make it more susceptible to ablation). In this manner, the targeted prostate tissue can be selectively ablated while leaving the urethra intact and unaffected. As described above, strong exogenous electrical fields can ablate tissue without significantly disrupting the extracellular matrix. The inflammatory response is relatively modest when compared to ablation from thermal injury. The proposed prostate ablation system exploits the tissue-specific susceptibility differences between the transitional epithelial cells of the urethra and the prostate tissue


In some embodiments, an apparatus includes an electrode controller configured to be operably coupled to a voltage pulse generator and a catheter. The voltage pulse generator is configured to produce a pulsed voltage waveform. The catheter includes a plurality of electrodes. The electrode controller is implemented in at least one of a memory or a processor, and includes a feedback module, a thermal control module and a pulse delivery module. The feedback module is configured to determine a temperature of a target tissue. The thermal control module is configured to produce a signal to control a cooling fluid to the catheter based on the temperature of the target tissue. The pulse delivery module is configured to deliver an output signal associated with the pulsed voltage waveform to the plurality of electrodes, and is further configured to shunt an excess current associated with the pulsed voltage waveform


In some embodiments, an apparatus includes an electrode controller configured to be operably coupled to a voltage pulse generator, a catheter and a heater. The voltage pulse generator is configured to produce a pulsed voltage waveform. The catheter includes a plurality of electrodes. The electrode controller is implemented in at least one of a memory or a processor, and includes a thermal control module and a pulse delivery module. The thermal control module is configured to produce a first signal to control a cooling fluid to the catheter. The thermal control module is configured to produce a second signal to control a temperature of a heater. The pulse delivery module configured to deliver an output signal associated with the pulsed voltage waveform to the plurality of electrodes. The pulse delivery module is further configured to shunt an excess current associated with the pulsed voltage waveform.


In some embodiments, a method includes receiving, at a feedback module of an electrode controller, a temperature signal associated with a temperature of a urethral wall against which a medical a catheter is disposed. The catheter includes a plurality of electrodes. A control signal based on the temperature signal is delivered to a cooling unit to produce a flow of cooling fluid to the catheter. An output signal associated with a pulsed voltage waveform is delivered to the plurality of electrodes.


In some embodiments, a non-transitory processor readable medium storing code representing instructions to be executed by a processor includes code to cause the processor to receive a temperature signal associated with a temperature of a urethral wall against which a medical a catheter is disposed. The medical catheter including a plurality of electrodes. The code further includes code to produce a control signal to a cooling unit to produce a flow of cooling fluid to the catheter. The control signal based on the temperature signal. The code further includes code to deliver an output signal associated with the pulsed voltage waveform to the plurality of electrodes when the target tissue is at the target temperature.


In some embodiments, a system includes a pulse generator unit, a controller unit, a flexible medical device and a fluid pump. The pulse generator unit is configured to produce a pulsed voltage waveform. The controller unit is connected to the pulse generator unit, and is configured to modulate pulses from the generator unit. The controller unit includes shunt circuitry configured to shunt excess current. The controller unit includes a thermal control module. The flexible medical device includes a plurality of electrodes and defines a series of ports through which a cooling fluid can flow. The flexible medical device is configured to be connected to the controller unit such that a voltage signal associated with the pulsed voltage waveform can be conveyed to the plurality of electrodes. The fluid pump is configured to produce the cooling flow in response to a cooling signal produced by the thermal control module of the controller unit. In some embodiments, the system optionally includes a trans-rectal probe including a probe head having a heater. The heater is configured to heat a portion of a prostate tissue in response to a cooling signal produced by the thermal control module of the controller unit.


In some embodiments, a system or method includes the use of temperature to selectively ablate tissue as the threshold of irreversible electroporation is temperature-dependent, for example with the use of pulses of cold fluid irrigation in the form of saline fluid. In this manner, epithelial tissue in the region of the urethral wall can be left intact, while at the same time the ablation is effectively applied only to deeper tissue structures adjacent to the urethral wall. The delivery of cold fluid can be suitably pulsed in order to ensure that only epithelial tissue is cooled while deeper tissue is not substantively cooled. Surprisingly, in some embodiments, the pulses of fluid flow can involve periodical infusions of warm fluid in time intervals between voltage pulses. In one embodiment, the control of fluid pulse and temperature parameters is also programmable.


In some embodiments, the temperature of the transurethral probe can be modulated by other suitable methods such as a closed-loop coolant, thermoelectric transduction, and/or resistive heating coils. A trans-rectal probe could be added to the apparatus to accentuate the delivery of thermal energy (radiant heat, infrared, microwave, ultrasound etc.). Using a two-probe technique the rectal probe could be arranged as a dedicated heating probe and the intra-urethral device as a dedicated cooling source.


The timing and intensity of thermal delivery are delivered in a manner to optimize the local tissue thermal environment. The goal is to maximally cool the tissues of the urethra and bladder that would be exposed to the ablation impulse while warming the targeted tissues of the prostate. The most direct way to achieve this is to start the cycle with warm irrigation or radiant energy to allow heat transfer into the surrounding prostate tissues followed by a short phase of cooling. The longer first phase would produce a relative steady state increase in the prostate tissue above the normal body temperature but not high enough to cause thermal tissue injury. The second, shorter phase delivers cooling to the local urethra and bladder in such a way as to quickly drop the local tissue temperature below normal body temperature. The ablation impulse would be delivered into tissue with a thermal gradient favoring preservation of the epithelial urethra while increasing susceptibility of the prostate tissues.


In some embodiments, an irreversible electroporation system is disclosed that includes a DC voltage/signal generator and a controller. Further, the controller is capable of applying control inputs with possibly programmable voltage pulse parameters as well as programmable selection of electrodes as cathodes or anodes. The generator can output waveforms that can be selected to generate a sequence of voltage pulses in either monophasic or biphasic forms and with either constant or progressively changing amplitudes. Methods of control and DC voltage application from a generator capable of selective excitation of sets of electrodes are disclosed.


In some embodiments, a method includes the treatment of benign prostatic hyperplasia. In one embodiment, a standard defibrillator can be utilized together with a switch to selectively apply a portion of the voltage pulse generated by the defibrillator unit, while excessive current is shunted away with a suitable shunt circuit.


The cooling irrigation fluid for any of the devices, systems and methods described herein can be any biocompatible fluid. In some embodiments, the current transfer properties of the fluid are of significant importance, and thus the irrigation fluid is formulated to facilitate the methods described herein. The irrigation used in the cooling phase can have a high electrolyte content (normal saline for example) with the possible inclusion of other biocompatible compounds to facilitate ablation and reduce local injury.


In some embodiments, the irreversible electroporation system described herein includes a DC voltage/signal generator and a controller unit for applying voltage pulses to electrodes. In one embodiment, the signal generator is capable of being configured to apply voltages to a selected multiplicity or a subset of electrodes on a transurethral minimally invasive catheter device. The controller is additionally capable of being programmable for voltage pulse parameters. In one embodiment where the device through which voltage pulses are applied also carries cooled fluid, the controller unit can also control fluid flow or pulse rate and fluid temperature.


The DC voltage is applied in brief pulses sufficient to cause irreversible electroporation and can be in the range of 0.5 kV to 10 kV and more preferably in the range 1 kV to 2.5 kV, so that a threshold electric field value in the range of 200-1000 Volts/cm is effectively achieved in the prostate tissue to be ablated. In one embodiment, the DC voltage value is selected directly by a user from a suitable dial, slider, touch screen, or any other user interface. The DC voltage pulse also results in a current flowing between the anode and cathode electrodes in the distal region of the catheter device that is inserted into the patient urethra, with the current entering the prostate tissue from the anode(s) and returning back through the cathode electrodes. The forward and return current paths (leads) are both inside the catheter. Areas of prostate tissue where the electric field is sufficiently large for irreversible electroporation are ablated during the DC voltage pulse application.


As used in this specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, the term “a member” is intended to mean a single member or a combination of members, “a material” is intended to mean one or more materials, “a processor” is intended to mean a single processor or multiple processors; and “memory” is intended to mean one or more memories, or a combination thereof.


As used herein, the terms “about” and “approximately” generally mean plus or minus 10% of the value stated. For example, about 0.5 would include 0.45 and 0.55, about 10 would include 9 to 11, about 1000 would include 900 to 1100.


A schematic diagram of the electroporation system according to an embodiment in one embodiment is shown in FIG. 1A. A DC voltage/signal generator 23 is driven by a controller unit 21 that interfaces with a computer device 24 by means of a two-way communication link 29. The controller can perform channel selection and routing functions for applying DC voltages to appropriate electrodes that have been selected by a user or by the computer 24, and apply the voltages via a multiplicity of leads (shown collectively as 26) to a catheter device 22. The catheter device 22, and any of the catheter devices described herein can be similar to the ablation catheters described in PCT Publication No. WO2014/025394, entitled “Catheters, Catheter Systems, and Methods for Puncturing Through a Tissue Structure,” filed on Mar. 14, 2013 (“the '394 PCT Application), which is incorporated herein by reference in its entirety.


Some leads from the controller 21 could also carry control signals to drive pulsatile fluid flow through the device and/or for fluid temperature control (not shown). The catheter device can also possibly send back information such as temperature data from other sensors back to the controller 21 as indicated by the data stream 25, possibly on separate leads. While the DC voltage generator 23 sends a DC voltage to the controller 21 through leads 27, the voltage generator is driven by control and timing inputs 28 from the controller unit 21. Multiple DC voltage pulses can be applied in a pulse train to ensure that sufficient tissue ablation has occurred. Further, the user can repeat the delivery of irreversible electroporation over several distinct pulse trains for further confidence.


In some embodiments, the electrode controller can include one or more modules and can automatically control the flow of fluid through a catheter (e.g., to produce a pulsed flow or the like), control heating of a particular portion of target tissue (e.g., the prostate), adjust a characteristic of the voltage waveform, or the like. For example, FIG. 1B shows an electroporation system according to an embodiment that includes an electrode controller 900 and a signal generator 925. In some embodiments, the signal generator 925 can be a cardiac defibrillator device. The electrode controller 900 is coupled to a computer 920 or other input/output device, and is configured to be operably coupled to a medical device 930. The medical device 930 can be one or more of the catheters of the types shown and described herein. Further the medical device 930 can be coupled to, disposed about and/or in contact with a target tissue T. For example, in some embodiments, the medical device can be disposed within a urethra of a patient. In this manner, as described herein, the electroporation system, including the electrode controller 900 and the signal generator 925, can deliver voltage pulses to the target tissue for therapeutic purposes.


Moreover, in some embodiments, the electrode controller 900 is optionally configured to be operably coupled to a medical device 935 that is distinct from the medical device 930. For example, the electrode controller 900 can optionally be coupled to a trans-rectal probe that includes a mechanism for delivering heat to a portion of the target tissue (e.g., the prostate).


The controller 900 can include a memory 911, a processor 910, and an input/output module (or interface) 901. The controller 900 can also include a temperature control module 902, a feedback module 905, and a pulse delivery module 908. The electrode controller 900 is coupled to a computer 920 or other input/output device via the input/output module (or interface) 901.


The processor 910 can be any processor configured to, for example, write data into and read data from the memory 911, and execute the instructions and/or methods stored within the memory 911. Furthermore, the processor 910 can be configured to control operation of the other modules within the controller (e.g., the temperature control module 902, the feedback module 905, and the pulse delivery module 908). Specifically, the processor 910 can receive a signal including user input, temperature data, distance measurements or the like and determine a set of electrodes to which voltage pulses should be applied, the desired timing and sequence of the voltage pulses and the like. In other embodiments, the processor 910 can be, for example, an application-specific integrated circuit (ASIC) or a combination of ASICs, which are designed to perform one or more specific functions. In yet other embodiments, the microprocessor can be an analog or digital circuit, or a combination of multiple circuits.


The memory device 911 can be any suitable device such as, for example, a read only memory (ROM) component, a random access memory (RAM) component, electronically programmable read only memory (EPROM), erasable electronically programmable read only memory (EEPROM), registers, cache memory, and/or flash memory. Any of the modules (the temperature control module 902, the feedback module 905, and the pulse delivery module 908) can be implemented by the processor 910 and/or stored within the memory 911.


As shown, the electrode controller 900 operably coupled to the signal generator 925. In some embodiments, the signal generator can be a cardiac defibrillator. The signal generator includes circuitry, components and/or code to produce a series of DC voltage pulses for delivery to electrodes included within the medical device 930. For example, in some embodiments, the signal generator 925 can be configured to produce a biphasic waveform having a pre-polarizing pulse followed by a polarizing pulse. The signal generator 925 can be any suitable signal generator of the types shown and described herein.


The pulse delivery module 908 of the electrode controller 900 includes circuitry, components and/or code to deliver an output signal associated with the pulsed voltage waveform produced by the signal generator 925. This signal (shown as signal 909) can be any signal of the types shown and described herein, and can be of a type and/or have characteristics to be therapeutically effective. In some embodiments, the pulse delivery module 908 receives input from other portions of the system, and can therefore send the signal 909 to the appropriate subset of electrodes, as described herein.


The electrode controller 900 includes the temperature control module 902. The temperature control module 902 includes circuitry, components and/or code to produce a control signal (identified as signal 903) that can be delivered to the device 935 and/or a control signal (identified as signal 903′) that can be delivered to either a coolant supply (not shown) or to the medical device 930. In this manner, the temperature control module 902 can facilitate heating of a first portion of the tissue (e.g., via the device 935) and/or cooling of a second portion of the tissue T (e.g., the urethral walls).


In some embodiment, the ablation controller and signal generator can be mounted on a rolling trolley, and the user can control the device using a touchscreen interface that is in the sterile field. The touchscreen can be for example an LCD touchscreen in a plastic housing mountable to a standard medical rail or post and can be used to select the electrodes for ablation and to ready the device to fire. The interface can for example be covered with a clear sterile plastic drape. In one embodiment, the operator can select the electrodes involved in the voltage pulse delivery. For example, in one embodiment the operator can select electrodes from the touchscreen with appropriate graphical buttons. In one embodiment, the ablation pulse train can be initiated by holding down a hand-held trigger button that is in the sterile field, possibly with the pulse train parameters (such as for example individual pulse parameters, number of pulses in the pulse train) having been programmed. The hand-held trigger button can be illuminated red to indicate that the device is “armed” and ready to ablate. The trigger button can be compatible for use in a sterile field and when attached to the controller can be illuminated a different color, for example white. When the device is firing, the trigger button flashes in sequence with the pulse delivery in a specific color such as red. The waveform of each delivered pulse is displayed on the touchscreen interface. While a touchscreen interface is one embodiment, other user interfaces can be used by a user to control the system such as for example a graphical display on a laptop or monitor display controlled by a standard computer mouse or joystick.


In some embodiments, the system (generator and controller) according to an embodiment can deliver rectangular-wave pulses with a peak maximum voltage of about 5 kV into a load with an impedance in the range of 30 Ohm to 3000 Ohm for a maximum duration of 200 μs, with a 100 μs maximum duration being still more preferred. Pulses can be delivered in a multiplexed and synchronized manner to a multi-electrode catheter inside the body with a duty cycle of up to 50% (for short bursts). The pulses can generally be delivered in bursts, such as for example a sequence of between 2 and 10 pulses interrupted by pauses of between 1 ms and 1000 ms. The multiplexer controller is capable of running an automated sequence to deliver the impulses/impulse trains (from the DC voltage signal/impulse generator) to the tissue target within the body. The controller system is capable of switching between subsets/nodes of electrodes located on the single use catheter.


The controllers and generators described herein can output waveforms that can be selected to generate a sequence of voltage pulses in either monophasic or biphasic forms and with either constant or progressively changing amplitudes. FIG. 2 shows a rectangular wave pulse train where the pulses 101 have a uniform height or maximum voltage. FIG. 3 shows an example of a balanced biphasic rectangular pulse train, where each positive voltage pulse such as 103 is immediately followed by a negative voltage pulse such as 104 of equal amplitude and opposite sign. While in this example the biphasic pulses are balanced with equal amplitudes of the positive and negative voltages, in other embodiments an unbalanced biphasic waveform could also be used as may be convenient for a given application. In some embodiments, generally biphasic voltage pulses are utilized to drive irreversible electroporation ablation in prostate tissue with the device and system of the present disclosure.


Yet another example of a waveform or pulse shape that can be generated by the system is illustrated in FIG. 4, which shows a progressive balanced rectangular pulse train, where each distinct biphasic pulse has equal-amplitude positive and negative voltages, but each pulse such as 107 is larger in amplitude than its immediate predecessor 106. Other variations such as a progressive unbalanced rectangular pulse train, or indeed a wide variety of other variations of pulse amplitude with respect to time can be conceived and implemented by those skilled in the art based on the teachings herein.


The time duration of each irreversible electroporation rectangular voltage pulse could lie in the range from 1 nanosecond to 10 milliseconds, with the range 10 microseconds to 1 millisecond being more preferable and the range 50 microseconds to 300 microseconds being still more preferable. The time interval between successive pulses of a pulse train could be in the range of 10 microseconds to 1 millisecond, with the range 50 microseconds to 300 microseconds being more preferable. The number of pulses applied in a single pulse train (with delays between individual pulses lying in the ranges just mentioned) can range from 1 to 100, with the range 1 to 10 being more preferable. As described in the foregoing, a pulse train can be driven by a user-controlled switch or button, in one embodiment preferably mounted on a hand-held joystick-like device. In one mode of operation a pulse train can be generated for every push of such a control button, while in an alternate mode of operation pulse trains can be generated with a pre-determined delay between successive pulse trains, for as long as the user-controlled switch or button is engaged by the user.


A catheter device for distal ablation with the electroporation system according to an embodiment is shown schematically in FIG. 5. The ablation catheter with shaft 162 has two electrodes disposed in the distal section of the catheter, with a relatively proximally placed electrode 164 of length L1 exposed on the catheter shaft and a relatively distally placed electrode 163 of length L2 also exposed on the catheter shaft. The catheter shaft is made of a material with high dielectric strength such as for example a polymer comprising Teflon. Both electrodes are metallic, and in one embodiment the anode could be poly-metallic in construction, for example comprising regions of Titanium and regions of Platinum. The catheter has a lumen shown as 161 and in one embodiment the distal tip portion 160 could have a diameter that is smaller than that at the relatively proximal shaft section 162, so that the tip is tapered, making for easier insertion into the urethra. In one embodiment the electrode lengths L1 and L2 could be different, while in an alternate embodiment they are closely similar in length. The catheter is inserted via the urethra and positioned with its distal portion abutting prostate tissue in the region of which tissue ablation is desired.



FIG. 6 schematically illustrates a catheter device with shaft 150 and distal electrodes 151 and 152 disposed longitudinally in a urethral vessel in a prostate tissue region, with urethral walls indicated by dashed lines, with inner vessel wall 153 and outer vessel wall 154 respectively. Thus the layer of tissue between lines 153 and 154 is epithelial tissue, while the tissue outside the outer vessel wall is prostate tissue in this schematic depiction. When the electrodes are activated with a voltage applied across them, an electric field is generated in the region around and between the electrodes, depicted schematically by field lines 155 in FIG. 6. In some embodiments, the catheter lumen carries a fluid flow of cooled fluid depicted by arrows 157; the fluid can be for instance a saline fluid which is harmlessly disposed of by the body. The temperature of the saline fluid can be about 55 degrees Fahrenheit or lower.


In some embodiments, the time for which a cold temperature is maintained at the patient contacting catheter surface is monitored and varied, so that the cooling control is applied in time in a pulse-like format. This is done in order to maintain a surface layer of tissue at a suitably low or cold temperature, while ensuring that deeper regions of tissue undergo no more than marginal cooling. For example, the thermal diffusivity D of skin tissue is known to be in the range of 0.11 mm2/s. From standard heat diffusion theory, in a time T the depth x to which a temperature change applied at the surface is propagated is given (in two dimensions) by x˜√{square root over (2DT)}. Thus, in 20 seconds of cooling, the depth x would be approximately 2 mm, which is about the thickness of skin tissue. In one mode of operation of the system according to an embodiment, the cooling of the electrodes is performed in discrete time intervals in the range of 10 seconds to 40 seconds, followed by a pulse train application, the entire duration of the pulse train being in the range of less than about 8 seconds. Thus, the application of cooling could also be performed in pulses.


The urethral wall tissue in the region between dashed lines 153 and 154 in FIG. 6 is then always at a cold temperature during voltage pulse application. This increases its irreversible electroporation threshold, thereby maintaining its integrity with no ablation occurring in this zone. At the same time prostate tissue beyond the urethral wall, for example in the region denoted 158 in FIG. 6, undergoes irreversible electroporation due to the sufficiently large electric fields in this region. The next ablation in the same tissue region is performed, if necessary, after another cooling pulse is applied over a discrete time interval, and so on. In one method according to an embodiment, a heating pulse could follow a cooling pulse in order to ensure that the temperature in the interior of the tissue does not fall below a threshold value. Suitably cold saline could generally be infused in small quantities in each pulse, for example at a rate in the range of a few milliliters/second or less.



FIG. 7 schematically depicts one embodiment of the transurethral catheter device according to an embodiment with multiple electrodes in its distal region. In this example, the catheter shaft 175 has four electrodes 170, 171, 172 and 173 disposed in its distal region. With electrode 172 chosen as anode and the other electrodes as cathodes, with an applied voltage the resulting electric field lines are indicated schematically by 176. The resulting electric field intensity would be locally high in the approximate region schematically shown as the region 177 inside the dashed-line ellipse, and this would serve as a selected zone of ablation. It should be clear that by choosing different electrodes or electrode combinations as anodes or cathodes, the desired zone of ablation can be varied. In one embodiment, as before the catheter can have a lumen carrying a pulsed flow of cold fluid in order to increase the electroporation threshold of the urethral wall. In this manner, tissue outside the urethral wall can be selectively ablated while leaving the urethral wall itself unaffected. In one embodiment the catheter device can have at least one temperature sensor such as a thermistor or thermocouple disposed in the distal portion of the device for monitoring temperature.


Isomagnitude contours for electric field lines corresponding to the catheter described in the previous paragraph and depicted in FIG. 7 are illustrated in FIG. 8. As before, the catheter shaft 175 has four electrodes 170, 171, 172 and 173 disposed in its distal region. Given a set of electrode polarities and tissue/material properties, Maxwell's equations can be solved for the electric field in the region surrounding the catheter. Results from such a computational simulation are illustrated in FIG. 8, where corresponding contours of equal electric field magnitude or isomagnitude contours were generated and are shown as contours 181 and 182 in FIG. 8. It is evident that the contours bulge outward preferentially near the source electrode 172. In this manner the treatment zone may be suitably tailored or customized as desired for the procedure at hand.



FIG. 9 is an illustration of an embodiment of an electroporation ablation catheter with a series of lateral ablation electrodes and a distal balloon. As shown in FIG. 9, the catheter has a through lumen 17 and a distal balloon 1 that is inflated from a port 4 through which for example a saline fluid is infused to expand the balloon. The catheter has a series of electrodes such as 3 arrayed in lateral pairs as shown in the top and bottom representations (rotated by 90 degrees about the catheter axis relative to each other) in FIG. 9, as well as a series of lateral ports 2 adjacent to respective electrodes. Electrodes leads 7 and 8 of opposite polarities are used to apply voltages of opposing polarities respectively on each electrode of a laterally opposing electrode pair. Proximal port 4 is used to infuse or withdraw saline or other fluid to expand or contract the distal balloon 1, while ports 5 and 6 are used for the circulation of cooling fluid (forward and backward flows). In use, the catheter is positioned in the urethra with the distal tip in the bladder; subsequently, the distal balloon is inflated, thereby holding the catheter in place within the urethra, with the region of catheter shaft with electrodes abutting prostate tissue. The through lumen 17 is used to drain the bladder as needed in the procedure. The series of electrodes on the device would be spaced with a separation between closest edges in the approximate range 1 mm to 7 mm. The catheter diameter would be approximately in the range of 2 mm; the small separation (approximately the catheter diameter) between opposing electrodes in a laterally opposed pair implies that a reduced voltage can be used to drive electroporation. The catheter shaft is constructed of flexible material such as Teflon that also has a suitably high dielectric strength.


As shown in FIG. 10, the cross section of the shaft of the catheter with lateral electrodes and lateral ports has a multiplicity of lumens. The central lumen 17 drains the bladder, while the electrode leads (of opposing polarities) pass through lumens 10 and 11. Lumen 16 carries saline or other fluid to inflate or deflate the distal balloon. Lumens 12 and 13 carry cooling fluid in one direction (forward, for example), while lumens 14 and 15 carry cooling fluid in an opposite direction (backward, for example), thereby in effect circulating cooling fluid through the lateral ports and maintaining a circulating saline pool in the urethra around the electrodes. The cooling fluid can be for example saline fluid at a temperature in the range between approximately 50 degrees Fahrenheit and 75 degrees Fahrenheit, so that it is significantly colder than normal body temperature. The cooling fluid reduces the temperature of the epithelial tissue of the urethral wall, correspondingly increasing the threshold electric field for irreversible electroporation. In this situation, the electric field generated between the lateral electrodes leaves the urethral wall tissue unaffected, while the electric field in the region of prostate tissue can drive irreversible electroporation there.



FIG. 11 provides a schematic depiction of electric field lines around the cross section of a catheter with a series of lateral ablation electrodes. In FIG. 11, laterally opposing electrodes 3 are shown on the left and right sides of the catheter shaft cross section, and when a voltage is applied across the lateral electrode pair, corresponding electric field lines 20 are schematically shown in the illustration.


The geometry of the catheter disposed in the urethra is illustrated schematically in cross section in FIG. 12. The urethra has a urethral wall 32 and the ablation catheter 30 according to an embodiment is disposed within the urethral cross section. Cooling fluid 31 circulated through the catheter's lateral ports as described above serves to lower the temperature of the urethral wall 32 and generally forms an annular space around the catheter. The cooling fluid is delivered in brief pulses no more than approximately between 10 seconds and 40 seconds in duration, as described earlier. In this manner, while the urethral wall is rapidly cooled due to proximity with the cooling fluid during the application of electroporation voltage pulses, the prostate tissue 33 external to the urethra and just adjacent to it is not cooled very much, and is thus susceptible to irreversible electroporation by the electric field generated between the catheter electrodes. The delivery of electroporation voltage pulses is arranged to occur while the cooling fluid is in circulation to cool the urethral wall, with the delivery of cooling fluid itself occurring in flow pulses that are of a longer duration than the electroporation voltage pulses as described in the foregoing.


In some embodiments, the prostate ablation system can further include a trans-rectal probe inserted into the rectum and placed in apposition to the prostate, with the trans-rectal probe incorporating a means of thermal energy delivery for example in the form of focused ultrasound, radiant heat source, infrared source, thermoelectric heating source, or microwave source or other such means of thermal energy delivery that are known in the art. As shown in FIG. 13, the trans-rectal probe 508 is inserted into the rectum 507, and the probe has a probe head 510 incorporating means for thermal energy delivery. The prostate 504 and the bladder 505 are indicated in FIG. 13, and the trans-urethral ablation catheter 501 is inserted into the urethra 503 by access through the penis 502. The ablation catheter has a distal balloon 506 that when inflated, as shown in FIG. 13, serves to lodge the distal portion of the catheter firmly within the bladder and thus the catheter itself firmly within the urethra with the ablation electrodes indicated as dots 511 positioned adjacent to the prostate.


The rectal probe 508 heats the prostate tissue by a relatively modest amount to stay within a safe range, generating a temperature increase preferably in the range of 3 to 10 degrees Fahrenheit. This thermal energy delivery could itself be pulsed, for example in pulses lasting between approximately 10 seconds and 60 seconds, depending on the mode of thermal energy delivery and the associated specific details of heat transfer to tissue. For example, in the case where the thermal energy is delivered by focused ultrasound by means of incorporating one or more ultrasound transducers and possibly ultrasound reflectors as well thereby generating a focal spot or focal zone for ultrasound within the prostate tissue, the local tissue temperature in the focal zone can be increased quite rapidly. The local tissue heating has the effect of decreasing the irreversible electroporation threshold electric field, thus making it possible to successfully ablate prostate tissue with generated electric fields that are not too large. In this case electric field values in the range of a few hundred Volts/cm would suffice to drive irreversible electroporation in the desired treatment zone in prostate tissue, while at the same time the cooled urethral wall (cooled with cooling fluid circulated through the ablation catheter) is left intact without being ablated.


Several variations of ablation catheter design or embodiment can be constructed as may be convenient from a manufacturing standpoint or for procedural ease of use. In one variation illustrated in FIG. 14, two views of an ablation catheter with fluid ports co-located with electrodes are shown in the top and bottom sketches (the two views differ by a 90 degree rotation about the catheter long axis). In this construction, the ablation catheter has a distal electrode 1 and a distal balloon 65, as well as a series of laterally opposed pairs of distal electrodes 3 incorporating fluid ports 2. The series of electrodes on the device would be spaced with a separation between closest edges in the approximate range 1 mm to 7 mm. Electrode leads 63 and 64 connect to electrodes on opposite lateral sides respectively. Fluid track or tube 60 carries fluid (for example, saline) to inflate or deflate the distal balloon 65, while fluid tubes 61 and 62 can support cooling fluid circulation flow in opposite directions (for example, forward and backward respectively). The lateral fluid ports permit the circulation of cooling fluid; thus cooling fluid exits the ports on one side of the catheter (for example, the left side of the catheter as seen looking down from the distal end) and enters the ports on the opposite side of the catheter (for example, the right side of the catheter as seen looking down from the distal end). In this manner the annular space between the catheter and the inner wall of the urethra is filled with cooling fluid along the portion of the catheter shaft with the electrodes and fluid ports. Furthermore, the catheter can possibly incorporate a through lumen for evacuation or draining of the bladder.


In another alternate embodiment of the ablation catheter according to an embodiment, as shown in FIG. 15, the catheter can have a distal tip electrode and a distal balloon, as well as a series of ring electrodes 3 and lateral fluid ports 2 disposed along a distal portion of the catheter shaft. The lateral fluid ports are used for circulation of cooling fluid, as described in the foregoing, while the ring electrodes and the tip electrode are used to generate an electric field for ablation with suitable voltage pulses, as described above. The series of electrodes on the device would be spaced with a separation between closest edges in the approximate range 1 mm to 7 mm. FIG. 16 shows a cut-away view of such a catheter where fluid ports 5 are visible from the inside of the shaft, while the cross-section view provided illustrates a set or multiplicity of lumens. A central lumen 41 serves to drain the bladder, while lumens 43 and 46 are cooling fluid irrigation lumens carrying fluid flow in opposite directions (for example, forward and backward respectively). Lumen 44 carries fluid to inflate or deflate the distal balloon, while lumens 42 and 45 act as passages for electrode leads of opposite polarities respectively and possibly also for cooling fluid irrigation/circulation.


In yet another alternate embodiment, the ablation catheter can have, as illustrated in FIG. 17, a distal tip electrode, a distal balloon, a long flexible electrode 3 (for example, in the form of a long helical winding of metallic composition) and a set of lateral ports 2 on either side of the catheter for circulation of cooling fluid. The series of lateral ports on the device would be spaced with a separation between closest edges in the approximate range 1 mm to 7 mm. As shown in the cut-away view of such a catheter in FIG. 18, fluid ports 3 are visible from the inside of the shaft, while the cross-section view provided illustrates a set or multiplicity of lumens. A central lumen 50 serves to drain the bladder, while lumens 52 and 54 are cooling fluid irrigation lumens carrying fluid flow in opposite directions (for example, forward and backward respectively). Lumen 55 carries fluid to inflate or deflate the distal balloon, while lumens 51 and 53 act as passages for electrode leads of opposite polarities respectively and possibly also for cooling fluid irrigation/circulation.


In still another alternate embodiment of ablation catheter shown in FIG. 19, left and right views of a catheter with proximal end 71 and distal end 72 are both shown for clarity (left and right views are marked L and R respectively), the catheter having a long flexible electrode 80 and lateral ports 6 for cooling fluid irrigation through the irrigation shaft 75 with lumen 77 for fluid irrigation as well as electrode leads. The distal electrode is not marked.


In the embodiments with a distal electrode, while the distal electrode can generally be either an anode or a cathode, in some embodiments it is a cathode, since this can reduce the likelihood of flash arcing. The various embodiments of ablation catheters described above can be used in Trans-Urethral Rectoscopy Procedures (TURP), where the tissue resection is performed by irreversible electroporation ablation. In such an application, as shown in FIG. 20, an ablation catheter device 401 with multiple electrodes is shown (two electrodes 402 and 403 marked in its distal portion are shown for schematic illustration purposes). The catheter in this embodiment can be connected to a pulse generator 409 in the form of a defibrillator unit, which could possibly be a standard commercial unit such as a Booker Box. The catheter can incorporate an IGBT switch, possibly disposed in the catheter handle 405. In some embodiments, the switch can even be mounted in a disposable unit or box 407 that connects to the catheter handle and interfaces with the defibrillator unit. In an alternate embodiment, the switch can be incorporated in the catheter handle. The switch unit is designed to operate in pulsed fashion so that for example only a discrete time interval of pulse, for example 700 microseconds of defibrillator output, is passed through the catheter in a set of discrete pulses. The switch unit also is capable of accepting a variety of DC voltage sources, and has an in-built shunt circuit to shed or shunt away excess current. In this manner, even a standard defibrillator could be used with the ablation catheter device described herein to generate irreversible electroporation. In particular, the ablation catheter device can be very beneficial in Trans-Urethral clinical applications such as TURP.


As shown in FIG. 21, in some embodiments the catheter handle 405 can further be connected to a fluid pump 413 capable of pumping cooled fluid such as cooled saline through the catheter. Preferably the pump is capable of delivering and controlling pulsatile fluid flow wherein the fluid is delivered in pulses. In one embodiment the saline pump can deliver either cooled or heated or warmed fluid, while in another embodiment the saline pump can deliver cooled fluid while a trans-rectal probe with a means of inducing heating of prostate tissue is also used in the procedure. As indicated by the dashed lines between switch unit 407 and fluid pump 413, the switch unit can also drive control signals to the pump for setting fluid pulse control parameters such as fluid temperature and flow. Furthermore, when the ablation catheter is used in conjunction with a trans-rectal probe, the switch unit is capable of suitably timing or coordinating the delivery of cooling fluid through the catheter and thermal energy delivery via the rectal probe. In some embodiments the thermal energy delivery from the rectal probe is also performed in pulsed fashion.


In an alternate embodiment, instead of a defibrillator unit, the signal generator box 409 could comprise a programmable pulse generator of the types previously described herein. In a further alternate embodiment, such programmability (for example, of electrode selection) can be made from the switch unit 407, possibly through connection to a computer or other user interface. Further, in one embodiment sensed temperature data from the distal portion of the medical device (from a thermistor or thermocouple, for example) can be used to adjust the temperature of the saline fluid flow.


While various specific examples and embodiments of systems and tools for selective tissue ablation with irreversible electroporation were described in the foregoing for illustrative and exemplary purposes, it should be clear that a wide variety of variations and alternate embodiments could be conceived or constructed by those skilled in the art based on the teachings according to an embodiment. While specific methods of control and DC voltage application from a generator capable of selective excitation of sets of electrodes were disclosed, persons skilled in the art would recognize that any of a wide variety of other control or user input methods and methods of electrode subset selection etc. can be implemented without departing from the scope according to an embodiment. Likewise, while the foregoing described a range of specific tools or devices for more effective and selective DC voltage application for irreversible electroporation through fluid irrigation and catheter devices, other device constructions or variations could be implemented by one skilled in the art by employing the principles and teachings disclosed herein without departing from the scope according to an embodiment in a variety of medical applications.


Furthermore, while the present disclosure describes specific embodiments and tools involving irrigation with saline fluids and the use of temperature to selectively ablate tissue by taking advantage of the temperature-dependence of the threshold of irreversible electroporation, it should be clear to one skilled in the art that a variety of methods and devices for steady or pulsed fluid delivery, or for tissue or electrode cooling, or thermal energy delivery via a trans-rectal probe, could be implemented utilizing the methods and principles taught herein without departing from the scope according to an embodiment.


Accordingly, while many variations of methods and tools disclosed here can be constructed, the scope according to an embodiment is limited only by the appended claims.

Claims
  • 1. An apparatus, comprising: an electrode controller configured to be operably coupled to a voltage pulse generator configured to produce a pulsed voltage waveform and a catheter including a plurality of electrodes, the electrode controller implemented in at least one of a memory or a processor, the electrode controller including a feedback module, a thermal control module and a pulse delivery module, the feedback module configured to determine a temperature of a target tissue, the thermal control module configured to produce a signal to control a cooling fluid to the catheter based on the temperature of the target tissue, the pulse delivery module configured to deliver an output signal associated with the pulsed voltage waveform to the plurality of electrodes, the pulse delivery module further configured to shunt an excess current associated with the pulsed voltage waveform.
  • 2. The apparatus of claim 1, wherein the voltage pulse generator unit is a cardiac defibrillator.
  • 3. The apparatus of claim 1, wherein the pulse delivery module is configured to select at least a first electrode from the plurality of electrodes and a second electrode from the plurality of electrodes and deliver the output signal associated with the pulsed voltage waveform to the first electrode and the second electrode.
  • 4. The apparatus of claim 1, wherein the pulse delivery module is configured to modulate a characteristic of the output signal, the characteristic including at least one of an amplitude of the output signal, a period of the output signal, or duration of the output signal.
  • 5. The apparatus of claim 1, wherein the pulse delivery module is configured produce the output signal by incorporating intervals with zero voltage into voltage pulses from the voltage pulse generator.
  • 6. The apparatus of claim 1, wherein the electrode controller is configured to interface with an external device to program at least one of an amplitude of the output signal, a period of the output signal, or a duration of the output signal.
  • 7. The apparatus of claim 1, further comprising: the catheter, a proximal end of the catheter including a handle, at least a portion of the electrode controller disposed within the handle.
  • 8. The apparatus of claim 1, wherein the thermal control module is configured to produce the signal to control at least one of a flow of the cooling fluid or a temperature of the cooling fluid.
  • 9. The apparatus of claim 1, wherein the thermal control module is configured to produce the signal to produce a pulsed flow of the cooling fluid.
  • 10. The apparatus of claim 1, wherein: the signal is a first signal;the target tissue is a portion of a urethra; andthe thermal control module is configured to produce a second signal to control a temperature of a heater, the heater configured to heat a portion of a prostate tissue.
  • 11. A non-transitory processor readable medium storing code representing instructions to be executed by a processor, the code comprising code to cause the processor to: receive a temperature signal associated with a temperature of a urethral wall against which a medical a catheter is disposed, the medical catheter including a plurality of electrodes;produce a first control signal to a cooling unit to produce a flow of cooling fluid to the catheter, the control signal based on the temperature signal, wherein the flow of cooling fluid to the catheter is a pulsed flow; anddeliver an output signal associated with a pulsed voltage waveform to the plurality of electrodes when the target tissue is at the target temperature.
  • 12. The non-transitory processor readable medium of claim 11, the code further configured to cause the processor to produce a second signal to control a temperature of a heater, the heater configured to heat a portion of a prostate tissue.
  • 13. An apparatus, comprising: a catheter shaft defining a flow passage;a plurality of electrodes coupled to a distal end portion of the catheter shaft; anda controller coupled to a proximal end portion of the catheter shaft, the controller configured to receive a voltage input from a pulse generator and produce a timed pulsed voltage waveform based on the voltage input to the plurality of electrodes, the controller configured to control a flow of fluid through the flow passage;wherein the pulse generator is a cardiac defibrillator.
  • 14. The apparatus of claim 13, wherein the controller is disposable.
  • 15. The apparatus of claim 13, further comprising a heater configured to heat a portion of a prostate tissue, wherein the controller is further configured to control a temperature of the heater.
  • 16. The apparatus of claim 15, wherein the heater is configured to produce a focused ultrasound energy pulse to heat the portion of the prostate tissue.
  • 17. The system of claim 15, wherein the heater is configured to produce an infrared energy pulse to heat the portion of the prostate tissue.
  • 18. The system of claim 13, wherein the flow of fluid through the flow passage is a pulsed flow.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patent application Ser. No. 16/595,224, filed Oct. 7, 2019, and now U.S. Pat. No. 11,241,282, which is a divisional application of U.S. patent application Ser. No. 15/354,507, filed Nov. 17, 2016 and now U.S. Pat. No. 10,433,906, issued Oct. 8, 2019, which is an application claiming priority to PCT Application No. PCT/US2015/035592 titled “METHOD AND APPARATUS FOR RAPID AND SELECTIVE TRANSURETHRAL TISSUE ABLATION”, filed Jun. 12, 2015, which claims the benefit of priority to U.S. Provisional Application Ser. No. 61/997,868, entitled “Methods and Apparatus for Rapid and Selective Transurethral Tissue Ablation,” filed Jun. 12, 2014, the entire disclosures of which are incorporated herein by reference in their entirety.

US Referenced Citations (701)
Number Name Date Kind
4200104 Harris Apr 1980 A
4470407 Hussein Sep 1984 A
4739759 Rexroth et al. Apr 1988 A
5234004 Hascoet Aug 1993 A
5242441 Avitall Sep 1993 A
5257635 Langberg Nov 1993 A
5281213 Milder et al. Jan 1994 A
5304214 Deford et al. Apr 1994 A
5306296 Wright et al. Apr 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5341807 Nardella Aug 1994 A
5342301 Saab Aug 1994 A
5398683 Edwards et al. Mar 1995 A
5443463 Stern et al. Aug 1995 A
5454370 Avitall Oct 1995 A
5515848 Corbett et al. May 1996 A
5531685 Hemmer et al. Jul 1996 A
5545161 Imran Aug 1996 A
5578040 Smith Nov 1996 A
5617854 Munsif Apr 1997 A
5624430 Eton et al. Apr 1997 A
5667491 Pliquett et al. Sep 1997 A
5672170 Cho et al. Sep 1997 A
5700243 Narciso, Jr. Dec 1997 A
5702438 Avitall Dec 1997 A
5706823 Wodlinger Jan 1998 A
5722400 Ockuly et al. Mar 1998 A
5722402 Swanson et al. Mar 1998 A
5749914 Janssen May 1998 A
5779699 Lipson Jul 1998 A
5788692 Campbell et al. Aug 1998 A
5810762 Hofmann Sep 1998 A
5833710 Jacobson Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5836942 Netherly et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5843154 Osypka Dec 1998 A
5849028 Chen Dec 1998 A
5860974 Abele Jan 1999 A
5863291 Schaer Jan 1999 A
5868736 Swanson et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5876336 Swanson et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5895404 Ruiz Apr 1999 A
5899917 Edwards et al. May 1999 A
5904709 Arndt et al. May 1999 A
5916158 Webster, Jr. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5928269 Alt Jul 1999 A
5928270 Ramsey, III Jul 1999 A
5938660 Swartz et al. Aug 1999 A
6002955 Willems et al. Dec 1999 A
6006131 Cooper et al. Dec 1999 A
6009351 Flachman Dec 1999 A
6014579 Pomeranz et al. Jan 2000 A
6029671 Stevens et al. Feb 2000 A
6033403 Tu et al. Mar 2000 A
6035238 Ingle et al. Mar 2000 A
6045550 Simpson et al. Apr 2000 A
6068653 LaFontaine May 2000 A
6071274 Thompson et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6074389 Levine et al. Jun 2000 A
6076012 Swanson et al. Jun 2000 A
6090104 Webster, Jr. Jul 2000 A
6096036 Bowe et al. Aug 2000 A
6113595 Muntermann Sep 2000 A
6119041 Pomeranz et al. Sep 2000 A
6120500 Bednarek et al. Sep 2000 A
6142993 Whayne et al. Nov 2000 A
6146381 Bowe et al. Nov 2000 A
6164283 Lesh Dec 2000 A
6167291 Barajas et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6216034 Hofmann et al. Apr 2001 B1
6219582 Hofstad et al. Apr 2001 B1
6223085 Dann et al. Apr 2001 B1
6231518 Grabek et al. May 2001 B1
6245064 Lesh et al. Jun 2001 B1
6251107 Schaer Jun 2001 B1
6251109 Hassett et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6272384 Simon et al. Aug 2001 B1
6287306 Kroll et al. Sep 2001 B1
6314963 Vaska et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6350263 Wetzig et al. Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6370412 Armoundas et al. Apr 2002 B1
6391024 Sun et al. May 2002 B1
6413255 Stern Jul 2002 B1
6447505 McGovern et al. Sep 2002 B2
6464699 Swanson Oct 2002 B1
6470211 Ideker et al. Oct 2002 B1
6502576 Lesh Jan 2003 B1
6503247 Swartz et al. Jan 2003 B2
6517534 McGovern et al. Feb 2003 B1
6527724 Fenici Mar 2003 B1
6527767 Wang et al. Mar 2003 B2
6592581 Bowe Jul 2003 B2
6595991 Toellner et al. Jul 2003 B2
6607520 Keane Aug 2003 B2
6613046 Jenkins et al. Sep 2003 B1
6623480 Kuo et al. Sep 2003 B1
6638278 Falwell et al. Oct 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669693 Friedman Dec 2003 B2
6702811 Stewart et al. Mar 2004 B2
6719756 Muntermann Apr 2004 B1
6723092 Brown et al. Apr 2004 B2
6728563 Rashidi Apr 2004 B2
6743225 Sanchez et al. Jun 2004 B2
6743226 Cosman et al. Jun 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6764486 Natale Jul 2004 B2
6780181 Kroll et al. Aug 2004 B2
6805128 Pless et al. Oct 2004 B1
6807447 Griffin, III Oct 2004 B2
6892091 Ben-Haim et al. May 2005 B1
6893438 Hall et al. May 2005 B2
6926714 Sra Aug 2005 B1
6955173 Lesh Oct 2005 B2
6960206 Keane Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6972016 Hill et al. Dec 2005 B2
6973339 Govari Dec 2005 B2
6979331 Hintringer et al. Dec 2005 B2
6984232 Vanney et al. Jan 2006 B2
6985776 Kane et al. Jan 2006 B2
6994706 Chornenky Feb 2006 B2
7001383 Keidar Feb 2006 B2
7041095 Wang et al. May 2006 B2
7113831 Hooven Sep 2006 B2
7171263 Darvish et al. Jan 2007 B2
7182725 Bonan et al. Feb 2007 B2
7195628 Falkenberg Mar 2007 B2
7207988 Leckrone et al. Apr 2007 B2
7207989 Pike et al. Apr 2007 B2
7229402 Diaz et al. Jun 2007 B2
7229437 Johnson et al. Jun 2007 B2
7250049 Roop et al. Jul 2007 B2
7285116 De et al. Oct 2007 B2
7285119 Stewart et al. Oct 2007 B2
7326208 Vanney et al. Feb 2008 B2
7346379 Eng et al. Mar 2008 B2
7367974 Haemmerich et al. May 2008 B2
7374567 Heuser May 2008 B2
7387629 Vanney et al. Jun 2008 B2
7387630 Mest Jun 2008 B2
7387636 Cohn et al. Jun 2008 B2
7416552 Paul et al. Aug 2008 B2
7419477 Simpson et al. Sep 2008 B2
7419489 Vanney et al. Sep 2008 B2
7422591 Phan Sep 2008 B2
7429261 Kunis et al. Sep 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7513896 Orszulak Apr 2009 B2
7527625 Knight et al. May 2009 B2
7578816 Boveja et al. Aug 2009 B2
7588567 Boveja et al. Sep 2009 B2
7623899 Worley et al. Nov 2009 B2
7678108 Chrisitian et al. Mar 2010 B2
7681579 Schwartz Mar 2010 B2
7771421 Stewart et al. Aug 2010 B2
7805182 Weese et al. Sep 2010 B2
7842031 Abboud et al. Nov 2010 B2
7850642 Moll et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7857808 Oral et al. Dec 2010 B2
7857809 Drysen Dec 2010 B2
7869865 Govari et al. Jan 2011 B2
7896873 Hiller et al. Mar 2011 B2
7917211 Zacouto Mar 2011 B2
7918819 Karmarkar et al. Apr 2011 B2
7918850 Govari et al. Apr 2011 B2
7922714 Stevens-Wright Apr 2011 B2
7955827 Rubinsky et al. Jun 2011 B2
8048067 Davalos et al. Nov 2011 B2
8048072 Verin et al. Nov 2011 B2
8100895 Panos et al. Jan 2012 B2
8100900 Prinz et al. Jan 2012 B2
8108069 Stahler et al. Jan 2012 B2
8133220 Lee et al. Mar 2012 B2
8137342 Crossman Mar 2012 B2
8145289 Calabro′ et al. Mar 2012 B2
8147486 Honour et al. Apr 2012 B2
8160690 Wilfley et al. Apr 2012 B2
8175680 Panescu May 2012 B2
8182477 Orszulak et al. May 2012 B2
8206384 Falwell et al. Jun 2012 B2
8206385 Stangenes et al. Jun 2012 B2
8216221 Ibrahim et al. Jul 2012 B2
8221411 Francischelli et al. Jul 2012 B2
8226648 Paul et al. Jul 2012 B2
8228065 Wirtz et al. Jul 2012 B2
8235986 Kulesa et al. Aug 2012 B2
8235988 Davis et al. Aug 2012 B2
8251986 Chornenky et al. Aug 2012 B2
8282631 Davalos et al. Oct 2012 B2
8287532 Carroll et al. Oct 2012 B2
8414508 Thapliyal et al. Apr 2013 B2
8430875 Ibrahim et al. Apr 2013 B2
8433394 Harlev et al. Apr 2013 B2
8449535 Deno et al. May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8463368 Harlev et al. Jun 2013 B2
8475450 Govari et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8500733 Watson Aug 2013 B2
8535304 Sklar et al. Sep 2013 B2
8538501 Venkatachalam et al. Sep 2013 B2
8562588 Hobbs et al. Oct 2013 B2
8568406 Harlev et al. Oct 2013 B2
8568410 Vakharia et al. Oct 2013 B2
8571635 McGee Oct 2013 B2
8571647 Harlev et al. Oct 2013 B2
8579897 Vakharia et al. Nov 2013 B2
8585695 Shih Nov 2013 B2
8588885 Hall et al. Nov 2013 B2
8597288 Christian Dec 2013 B2
8608735 Govari et al. Dec 2013 B2
8628522 Ibrahim et al. Jan 2014 B2
8632534 Pearson et al. Jan 2014 B2
8647338 Chornenky et al. Feb 2014 B2
8708952 Cohen et al. Apr 2014 B2
8734442 Cao et al. May 2014 B2
8771267 Kunis et al. Jul 2014 B2
8795310 Fung et al. Aug 2014 B2
8808273 Caples et al. Aug 2014 B2
8808281 Emmons et al. Aug 2014 B2
8834461 Werneth et al. Sep 2014 B2
8834464 Stewart et al. Sep 2014 B2
8868169 Narayan et al. Oct 2014 B2
8876817 Avitall et al. Nov 2014 B2
8880195 Azure Nov 2014 B2
8886309 Luther et al. Nov 2014 B2
8903488 Callas et al. Dec 2014 B2
8920411 Gelbart et al. Dec 2014 B2
8926589 Govari Jan 2015 B2
8932287 Gelbart et al. Jan 2015 B2
8945117 Bencini Feb 2015 B2
8979841 Kunis et al. Mar 2015 B2
8986278 Fung et al. Mar 2015 B2
8996091 De et al. Mar 2015 B2
9002442 Harley et al. Apr 2015 B2
9005189 Davalos et al. Apr 2015 B2
9005194 Oral et al. Apr 2015 B2
9011425 Fischer et al. Apr 2015 B2
9044245 Condie et al. Jun 2015 B2
9055959 Vaska et al. Jun 2015 B2
9072518 Swanson Jul 2015 B2
9078667 Besser et al. Jul 2015 B2
9101374 Hoch et al. Aug 2015 B1
9113911 Sherman Aug 2015 B2
9119533 Ghaffari Sep 2015 B2
9119634 Gelbart et al. Sep 2015 B2
9131897 Harada et al. Sep 2015 B2
9155590 Mathur Oct 2015 B2
9162037 Belson et al. Oct 2015 B2
9179972 Olson Nov 2015 B2
9186481 Avitall et al. Nov 2015 B2
9192769 Donofrio et al. Nov 2015 B2
9204916 Lalonde Dec 2015 B2
9211405 Mahapatra et al. Dec 2015 B2
9216055 Spence et al. Dec 2015 B2
9233248 Luther et al. Jan 2016 B2
9237926 Nollert et al. Jan 2016 B2
9262252 Kirkpatrick et al. Feb 2016 B2
9277957 Long et al. Mar 2016 B2
9282910 Narayan et al. Mar 2016 B2
9289258 Cohen Mar 2016 B2
9289606 Paul et al. Mar 2016 B2
9295516 Pearson et al. Mar 2016 B2
9301801 Scheib Apr 2016 B2
9351789 Novichenok et al. May 2016 B2
9375268 Long Jun 2016 B2
9387031 Stewart et al. Jul 2016 B2
9414881 Callas et al. Aug 2016 B2
9468495 Kunis et al. Oct 2016 B2
9474486 Eliason et al. Oct 2016 B2
9474574 Brahim et al. Oct 2016 B2
9480525 Lopes et al. Nov 2016 B2
9486272 Bonyak et al. Nov 2016 B2
9486273 Lopes et al. Nov 2016 B2
9492227 Lopes et al. Nov 2016 B2
9492228 Lopes et al. Nov 2016 B2
9510888 Jean-Pierre Dec 2016 B2
9517103 Panescu et al. Dec 2016 B2
9526573 Lopes et al. Dec 2016 B2
9532831 Reinders et al. Jan 2017 B2
9539010 Gagner et al. Jan 2017 B2
9554848 Stewart et al. Jan 2017 B2
9554851 Sklar et al. Jan 2017 B2
9700368 Callas et al. Jul 2017 B2
9724170 Mickelsen Aug 2017 B2
9757193 Zarins et al. Sep 2017 B2
9782099 Williams et al. Oct 2017 B2
9795442 Salahieh et al. Oct 2017 B2
9801681 Laske et al. Oct 2017 B2
9808304 Lalonde Nov 2017 B2
9861802 Mickelsen Jan 2018 B2
9913685 Clark et al. Mar 2018 B2
9931487 Quinn et al. Apr 2018 B2
9987081 Bowers et al. Jun 2018 B1
9999465 Long et al. Jun 2018 B2
10010368 Laske et al. Jul 2018 B2
10016232 Bowers et al. Jul 2018 B1
10130423 Viswanathan et al. Nov 2018 B1
10172673 Viswanathan et al. Jan 2019 B2
10194818 Williams et al. Feb 2019 B2
10285755 Stewart et al. May 2019 B2
10322286 Viswanathan et al. Jun 2019 B2
10433906 Mickelsen Oct 2019 B2
10433908 Viswanathan et al. Oct 2019 B2
10512505 Raju Dec 2019 B2
10512779 Viswanathan et al. Dec 2019 B2
10517672 Long Dec 2019 B2
10617467 Viswanathan et al. Apr 2020 B2
10660702 Viswanathan et al. May 2020 B2
20010000791 Suorsa et al. May 2001 A1
20010007070 Stewart et al. Jul 2001 A1
20010044624 Seraj et al. Nov 2001 A1
20020052602 Wang et al. May 2002 A1
20020058933 Christopherson et al. May 2002 A1
20020077627 Johnson et al. Jun 2002 A1
20020087169 Brock et al. Jul 2002 A1
20020091384 Hooven et al. Jul 2002 A1
20020095176 Prestel Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020156526 Hlavka et al. Oct 2002 A1
20020161323 Miller et al. Oct 2002 A1
20020169445 Jain et al. Nov 2002 A1
20020177765 Bowe et al. Nov 2002 A1
20020183638 Swanson Dec 2002 A1
20030014098 Quijano et al. Jan 2003 A1
20030018374 Paulos Jan 2003 A1
20030023287 Edwards et al. Jan 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030050637 Maguire et al. Mar 2003 A1
20030060856 Chornenky et al. Mar 2003 A1
20030114849 Ryan Jun 2003 A1
20030125729 Hooven et al. Jul 2003 A1
20030130598 Manning et al. Jul 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030204161 Ferek-Petric Oct 2003 A1
20030229379 Maynard Dec 2003 A1
20040039382 Kroll et al. Feb 2004 A1
20040049181 Stewart et al. Mar 2004 A1
20040049182 Koblish et al. Mar 2004 A1
20040082859 Schaer Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087939 Eggers et al. May 2004 A1
20040111087 Stern et al. Jun 2004 A1
20040199157 Palanker et al. Oct 2004 A1
20040231683 Eng et al. Nov 2004 A1
20040236360 Cohn et al. Nov 2004 A1
20040254607 Wittenberger et al. Dec 2004 A1
20040267337 Hayzelden Dec 2004 A1
20050033282 Hooven Feb 2005 A1
20050187545 Hooven et al. Aug 2005 A1
20050222632 Obino Oct 2005 A1
20050251130 Boveja et al. Nov 2005 A1
20050261672 Deem et al. Nov 2005 A1
20060009755 Sra Jan 2006 A1
20060009759 Chrisitian et al. Jan 2006 A1
20060015095 Desinger et al. Jan 2006 A1
20060015165 Bertolero et al. Jan 2006 A1
20060024359 Walker et al. Feb 2006 A1
20060058781 Long Mar 2006 A1
20060111702 Oral et al. May 2006 A1
20060142801 Demarais et al. Jun 2006 A1
20060167448 Kozel Jul 2006 A1
20060217703 Chornenky et al. Sep 2006 A1
20060241734 Marshall et al. Oct 2006 A1
20060264752 Rubinsky et al. Nov 2006 A1
20060270900 Chin et al. Nov 2006 A1
20060287648 Schwartz Dec 2006 A1
20060293730 Rubinsky et al. Dec 2006 A1
20060293731 Rubinsky et al. Dec 2006 A1
20070005053 Dando Jan 2007 A1
20070021744 Creighton Jan 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070066972 Ormsby et al. Mar 2007 A1
20070129721 Phan et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070156135 Rubinsky et al. Jul 2007 A1
20070167740 Grunewald et al. Jul 2007 A1
20070167940 Stevens-Wright Jul 2007 A1
20070173878 Heuser Jul 2007 A1
20070208329 Ward et al. Sep 2007 A1
20070225589 Viswanathan Sep 2007 A1
20070249923 Keenan Oct 2007 A1
20070260223 Scheibe et al. Nov 2007 A1
20070270792 Hennemann et al. Nov 2007 A1
20080009855 Hamou Jan 2008 A1
20080033426 Machell Feb 2008 A1
20080065061 Viswanathan Mar 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080091195 Sliwa et al. Apr 2008 A1
20080103545 Bolea et al. May 2008 A1
20080132885 Rubinsky et al. Jun 2008 A1
20080161789 Thao et al. Jul 2008 A1
20080172048 Martin et al. Jul 2008 A1
20080200913 Viswanathan Aug 2008 A1
20080208118 Goldman Aug 2008 A1
20080243214 Koblish Oct 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080300574 Belson et al. Dec 2008 A1
20080300588 Groth et al. Dec 2008 A1
20090024084 Khosla et al. Jan 2009 A1
20090048591 Ibrahim et al. Feb 2009 A1
20090062788 Long et al. Mar 2009 A1
20090076496 Azure Mar 2009 A1
20090076500 Azure Mar 2009 A1
20090105654 Kurth et al. Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090149917 Whitehurst et al. Jun 2009 A1
20090163905 Winkler et al. Jun 2009 A1
20090228003 Sinelnikov Sep 2009 A1
20090240248 Deford et al. Sep 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090281477 Mikus et al. Nov 2009 A1
20090306651 Schneider Dec 2009 A1
20100004623 Hamilton et al. Jan 2010 A1
20100023004 Francischelli et al. Jan 2010 A1
20100137861 Soroff et al. Jun 2010 A1
20100185140 Kassab et al. Jul 2010 A1
20100185186 Longoria Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100191232 Boveda Jul 2010 A1
20100241185 Mahapatra et al. Sep 2010 A1
20100261994 Davalos et al. Oct 2010 A1
20100274238 Klimovitch Oct 2010 A1
20100280513 Juergen et al. Nov 2010 A1
20100280539 Miyoshi et al. Nov 2010 A1
20100292687 Kauphusman et al. Nov 2010 A1
20100312096 Guttman et al. Dec 2010 A1
20100312300 Ryu et al. Dec 2010 A1
20110028962 Werneth et al. Feb 2011 A1
20110028964 Edwards Feb 2011 A1
20110040199 Hopenfeld Feb 2011 A1
20110098694 Long Apr 2011 A1
20110106221 Neal et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110144524 Fish et al. Jun 2011 A1
20110144633 Govari Jun 2011 A1
20110160785 Mori et al. Jun 2011 A1
20110190659 Long et al. Aug 2011 A1
20110190727 Edmunds et al. Aug 2011 A1
20110213231 Hall et al. Sep 2011 A1
20110276047 Sklar et al. Nov 2011 A1
20110276075 Fung et al. Nov 2011 A1
20110288544 Verin et al. Nov 2011 A1
20110288547 Morgan et al. Nov 2011 A1
20110313417 De et al. Dec 2011 A1
20120029512 Willard et al. Feb 2012 A1
20120046570 Villegas et al. Feb 2012 A1
20120053581 Wittkampf et al. Mar 2012 A1
20120059255 Paul et al. Mar 2012 A1
20120071872 Rubinsky et al. Mar 2012 A1
20120078320 Schotzko et al. Mar 2012 A1
20120078343 Fish Mar 2012 A1
20120089089 Swain et al. Apr 2012 A1
20120095459 Callas et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120158021 Morrill Jun 2012 A1
20120165667 Altmann et al. Jun 2012 A1
20120172859 Condie et al. Jul 2012 A1
20120172867 Ryu et al. Jul 2012 A1
20120197100 Razavi et al. Aug 2012 A1
20120209260 Lambert et al. Aug 2012 A1
20120220998 Long et al. Aug 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120283582 Mahapatra et al. Nov 2012 A1
20120303019 Zhao et al. Nov 2012 A1
20120310052 Mahapatra et al. Dec 2012 A1
20120310230 Willis Dec 2012 A1
20120310237 Swanson Dec 2012 A1
20120316557 Sartor et al. Dec 2012 A1
20130030430 Stewart et al. Jan 2013 A1
20130060247 Sklar et al. Mar 2013 A1
20130060248 Sklar et al. Mar 2013 A1
20130079768 De et al. Mar 2013 A1
20130090651 Smith Apr 2013 A1
20130096655 Moffitt et al. Apr 2013 A1
20130103027 Sklar et al. Apr 2013 A1
20130103064 Arenson et al. Apr 2013 A1
20130131662 Wittkampf May 2013 A1
20130158538 Govari Jun 2013 A1
20130158621 Ding et al. Jun 2013 A1
20130172715 Just et al. Jul 2013 A1
20130172864 Brahim et al. Jul 2013 A1
20130172875 Govari et al. Jul 2013 A1
20130184702 Neal et al. Jul 2013 A1
20130218157 Callas et al. Aug 2013 A1
20130226174 Ibrahim et al. Aug 2013 A1
20130237984 Sklar Sep 2013 A1
20130253415 Sano et al. Sep 2013 A1
20130296679 Condie et al. Nov 2013 A1
20130310829 Cohen Nov 2013 A1
20130317385 Sklar et al. Nov 2013 A1
20130331831 Werneth et al. Dec 2013 A1
20130338467 Grasse et al. Dec 2013 A1
20140005664 Govari et al. Jan 2014 A1
20140024911 Harlev et al. Jan 2014 A1
20140039288 Hue-Teh Feb 2014 A1
20140051993 McGee Feb 2014 A1
20140052118 Laske et al. Feb 2014 A1
20140052126 Long et al. Feb 2014 A1
20140052216 Long et al. Feb 2014 A1
20140058377 Deem et al. Feb 2014 A1
20140081113 Cohen et al. Mar 2014 A1
20140100563 Govari et al. Apr 2014 A1
20140107644 Falwell et al. Apr 2014 A1
20140142408 De et al. May 2014 A1
20140148804 Ward et al. May 2014 A1
20140163480 Govari et al. Jun 2014 A1
20140163546 Govari et al. Jun 2014 A1
20140171942 Werneth et al. Jun 2014 A1
20140180035 Anderson Jun 2014 A1
20140187916 Clark et al. Jul 2014 A1
20140194716 Diep et al. Jul 2014 A1
20140194867 Fish et al. Jul 2014 A1
20140200567 Cox et al. Jul 2014 A1
20140235986 Harlev et al. Aug 2014 A1
20140235988 Ghosh Aug 2014 A1
20140235989 Wodlinger et al. Aug 2014 A1
20140243851 Cohen et al. Aug 2014 A1
20140276760 Bonyak et al. Sep 2014 A1
20140276782 Paskar Sep 2014 A1
20140276791 Ku et al. Sep 2014 A1
20140288556 Ibrahim et al. Sep 2014 A1
20140303721 Fung et al. Oct 2014 A1
20140343549 Spear et al. Nov 2014 A1
20140364845 Rashidi Dec 2014 A1
20140371613 Narayan et al. Dec 2014 A1
20150005767 Werneth et al. Jan 2015 A1
20150011995 Avitall et al. Jan 2015 A1
20150066108 Shi et al. Mar 2015 A1
20150119674 Fischell et al. Apr 2015 A1
20150126840 Thakur et al. May 2015 A1
20150133914 Koblish May 2015 A1
20150138977 Dacosta May 2015 A1
20150141978 Subramaniam et al. May 2015 A1
20150141982 Lee May 2015 A1
20150142041 Kendale et al. May 2015 A1
20150148796 Bencini May 2015 A1
20150150472 Harlev et al. Jun 2015 A1
20150157402 Kunis et al. Jun 2015 A1
20150157412 Wallace et al. Jun 2015 A1
20150164584 Davalos et al. Jun 2015 A1
20150173824 Davalos et al. Jun 2015 A1
20150173828 Avitall Jun 2015 A1
20150174404 Rousso et al. Jun 2015 A1
20150182740 Mickelsen Jul 2015 A1
20150196217 Harlev et al. Jul 2015 A1
20150223726 Harlev et al. Aug 2015 A1
20150230699 Berul et al. Aug 2015 A1
20150258344 Tandri et al. Sep 2015 A1
20150265342 Long et al. Sep 2015 A1
20150265344 Aktas et al. Sep 2015 A1
20150272656 Chen Oct 2015 A1
20150272664 Cohen Oct 2015 A9
20150272667 Govari et al. Oct 2015 A1
20150282729 Harlev et al. Oct 2015 A1
20150289923 Davalos et al. Oct 2015 A1
20150304879 Dacosta Oct 2015 A1
20150320481 Cosman et al. Nov 2015 A1
20150321021 Tandri et al. Nov 2015 A1
20150342532 Basu et al. Dec 2015 A1
20150343212 Rousso et al. Dec 2015 A1
20150351836 Prutchi Dec 2015 A1
20150359583 Swanson Dec 2015 A1
20160000500 Salahieh et al. Jan 2016 A1
20160008061 Fung et al. Jan 2016 A1
20160008065 Gliner et al. Jan 2016 A1
20160029960 Toth et al. Feb 2016 A1
20160038772 Thapliyal et al. Feb 2016 A1
20160051204 Harlev et al. Feb 2016 A1
20160051324 Stewart et al. Feb 2016 A1
20160058493 Neal et al. Mar 2016 A1
20160058506 Spence et al. Mar 2016 A1
20160066993 Avitall et al. Mar 2016 A1
20160074679 Thapliyal et al. Mar 2016 A1
20160095531 Narayan et al. Apr 2016 A1
20160095642 Deno et al. Apr 2016 A1
20160095653 Lambert et al. Apr 2016 A1
20160100797 Mahapatra et al. Apr 2016 A1
20160100884 Fay et al. Apr 2016 A1
20160106498 Highsmith et al. Apr 2016 A1
20160106500 Olson Apr 2016 A1
20160113709 Maor Apr 2016 A1
20160113712 Cheung et al. Apr 2016 A1
20160120564 Kirkpatrick et al. May 2016 A1
20160128770 Afonso et al. May 2016 A1
20160166167 Narayan et al. Jun 2016 A1
20160166310 Stewart et al. Jun 2016 A1
20160166311 Long et al. Jun 2016 A1
20160174865 Stewart et al. Jun 2016 A1
20160183877 Williams et al. Jun 2016 A1
20160184003 Srimathveeravalli et al. Jun 2016 A1
20160184004 Hull et al. Jun 2016 A1
20160213282 Leo et al. Jul 2016 A1
20160220307 Miller et al. Aug 2016 A1
20160235470 Callas et al. Aug 2016 A1
20160249972 Klink Sep 2016 A1
20160256682 Paul et al. Sep 2016 A1
20160287314 Arena et al. Oct 2016 A1
20160310211 Long Oct 2016 A1
20160324564 Gerlach et al. Nov 2016 A1
20160324573 Mickelson et al. Nov 2016 A1
20160331441 Konings Nov 2016 A1
20160331459 Townley et al. Nov 2016 A1
20160338770 Bar-Tal et al. Nov 2016 A1
20160354142 Pearson et al. Dec 2016 A1
20160361109 Weaver et al. Dec 2016 A1
20170001016 De Ridder Jan 2017 A1
20170035499 Stewart et al. Feb 2017 A1
20170042449 Deno et al. Feb 2017 A1
20170042615 Salahieh et al. Feb 2017 A1
20170056648 Syed et al. Mar 2017 A1
20170065330 Mickelsen et al. Mar 2017 A1
20170065339 Mickelsen Mar 2017 A1
20170065340 Long Mar 2017 A1
20170065343 Mickelsen Mar 2017 A1
20170071543 Basu et al. Mar 2017 A1
20170095291 Harrington et al. Apr 2017 A1
20170105793 Cao et al. Apr 2017 A1
20170120048 He et al. May 2017 A1
20170146584 Daw et al. May 2017 A1
20170151014 Perfler Jun 2017 A1
20170151029 Mickelsen Jun 2017 A1
20170172654 Wittkampf et al. Jun 2017 A1
20170181795 Debruyne Jun 2017 A1
20170189097 Viswanathan et al. Jul 2017 A1
20170215953 Long et al. Aug 2017 A1
20170245928 Xiao et al. Aug 2017 A1
20170246455 Athos et al. Aug 2017 A1
20170312024 Harlev et al. Nov 2017 A1
20170312025 Harlev et al. Nov 2017 A1
20170312027 Harlev et al. Nov 2017 A1
20180001056 Leeflang et al. Jan 2018 A1
20180028252 Lalonde Feb 2018 A1
20180042674 Mickelsen Feb 2018 A1
20180042675 Long Feb 2018 A1
20180043153 Viswanathan et al. Feb 2018 A1
20180064488 Long et al. Mar 2018 A1
20180085160 Viswanathan et al. Mar 2018 A1
20180093088 Mickelsen Apr 2018 A1
20180133460 Townley et al. May 2018 A1
20180161093 Basu et al. Jun 2018 A1
20180168511 Hall et al. Jun 2018 A1
20180184982 Basu et al. Jul 2018 A1
20180193090 De et al. Jul 2018 A1
20180200497 Mickelsen Jul 2018 A1
20180235496 Wu et al. Aug 2018 A1
20180256109 Wu et al. Sep 2018 A1
20180280080 Govari et al. Oct 2018 A1
20180303488 Hill Oct 2018 A1
20180303543 Stewart et al. Oct 2018 A1
20180311497 Viswanathan et al. Nov 2018 A1
20180344202 Bar-Tal et al. Dec 2018 A1
20180344393 Gruba et al. Dec 2018 A1
20180360531 Holmes et al. Dec 2018 A1
20180360534 Teplitsky et al. Dec 2018 A1
20190015007 Rottmann et al. Jan 2019 A1
20190015638 Gruba et al. Jan 2019 A1
20190030328 Stewart et al. Jan 2019 A1
20190046791 Ebbers et al. Feb 2019 A1
20190069950 Viswanathan et al. Mar 2019 A1
20190076179 Babkin et al. Mar 2019 A1
20190125439 Rohl et al. May 2019 A1
20190125788 Gruba et al. May 2019 A1
20190143106 Dewitt et al. May 2019 A1
20190151015 Viswanathan et al. May 2019 A1
20190175263 Altmann et al. Jun 2019 A1
20190183378 Mosesov et al. Jun 2019 A1
20190183567 Govari et al. Jun 2019 A1
20190192223 Rankin Jun 2019 A1
20190201089 Waldstreicher et al. Jul 2019 A1
20190201688 Olson Jul 2019 A1
20190209235 Stewart et al. Jul 2019 A1
20190223948 Stewart et al. Jul 2019 A1
20190231421 Viswanathan et al. Aug 2019 A1
20190231425 Waldstreicher et al. Aug 2019 A1
20190254735 Stewart et al. Aug 2019 A1
20190269912 Viswanathan et al. Sep 2019 A1
20190298442 Ogata et al. Oct 2019 A1
20190307500 Byrd et al. Oct 2019 A1
20190350647 Ramberg et al. Nov 2019 A1
20190350649 Sutermeister et al. Nov 2019 A1
20200008869 Byrd Jan 2020 A1
20200008870 Gruba et al. Jan 2020 A1
20200009378 Stewart et al. Jan 2020 A1
20200038104 Mickelsen Feb 2020 A1
20200046423 Viswanathan et al. Feb 2020 A1
20200093539 Long et al. Mar 2020 A1
Foreign Referenced Citations (99)
Number Date Country
1042990 Oct 2000 EP
1125549 Aug 2001 EP
0797956 Jun 2003 EP
1340469 Sep 2003 EP
1127552 Jun 2006 EP
1803411 Jul 2007 EP
1009303 Jun 2009 EP
2213729 Aug 2010 EP
2382935 Nov 2011 EP
2425871 Mar 2012 EP
2532320 Dec 2012 EP
2587275 May 2013 EP
2663227 Nov 2013 EP
1909678 Jan 2014 EP
2217165 Mar 2014 EP
2376193 Mar 2014 EP
2708181 Mar 2014 EP
2777579 Sep 2014 EP
2777585 Sep 2014 EP
2934307 Oct 2015 EP
3056242 Aug 2016 EP
3111871 Jan 2017 EP
3151773 Apr 2018 EP
06-507797 Sep 1994 JP
2000-508196 Jul 2000 JP
2005-516666 Jun 2005 JP
2006-506184 Feb 2006 JP
2008-538997 Nov 2008 JP
2009-500129 Jan 2009 JP
2011-509158 Mar 2011 JP
2012-050538 Mar 2012 JP
9207622 May 1992 WO
9221278 Dec 1992 WO
9221285 Dec 1992 WO
9407413 Apr 1994 WO
9724073 Jul 1997 WO
9725917 Jul 1997 WO
9737719 Oct 1997 WO
9904851 Feb 1999 WO
9922659 May 1999 WO
9956650 Nov 1999 WO
9959486 Nov 1999 WO
0256782 Jul 2002 WO
0353289 Jul 2003 WO
0365916 Aug 2003 WO
2004045442 Jun 2004 WO
2004086994 Oct 2004 WO
2005046487 May 2005 WO
2006115902 Nov 2006 WO
2007006055 Jan 2007 WO
2007079438 Jul 2007 WO
2009082710 Jul 2009 WO
2009089343 Jul 2009 WO
2009137800 Nov 2009 WO
2010014480 Feb 2010 WO
2011028310 Mar 2011 WO
2011154805 Dec 2011 WO
2012051433 Apr 2012 WO
2012097067 Jul 2012 WO
2012153928 Nov 2012 WO
2013019385 Feb 2013 WO
2014025394 Feb 2014 WO
2014031800 Feb 2014 WO
2014036439 Mar 2014 WO
2014100579 Jun 2014 WO
2014160832 Oct 2014 WO
2015066322 May 2015 WO
2015099786 Jul 2015 WO
2015103530 Jul 2015 WO
2015103574 Jul 2015 WO
2015130824 Sep 2015 WO
2015140741 Sep 2015 WO
2015143327 Sep 2015 WO
2015171921 Nov 2015 WO
2015175944 Nov 2015 WO
2015192018 Dec 2015 WO
2015192027 Dec 2015 WO
2016059027 Apr 2016 WO
2016060983 Apr 2016 WO
2016081650 May 2016 WO
2016090175 Jun 2016 WO
2017093926 Jun 2017 WO
2017119934 Jul 2017 WO
2017120169 Jul 2017 WO
2017192477 Nov 2017 WO
2017192495 Nov 2017 WO
2017201504 Nov 2017 WO
2017218734 Dec 2017 WO
2018005511 Jan 2018 WO
2018106569 Jun 2018 WO
2018200800 Nov 2018 WO
2019023259 Jan 2019 WO
2019023280 Jan 2019 WO
2019035071 Feb 2019 WO
2019133606 Jul 2019 WO
2019133608 Jul 2019 WO
2019136218 Jul 2019 WO
2019181612 Sep 2019 WO
2019234133 Dec 2019 WO
Non-Patent Literature Citations (11)
Entry
Du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013).
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages.
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007].
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016).
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014).
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014).
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014).
Van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015).
Van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014).
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011).
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012).
Related Publications (1)
Number Date Country
20220133405 A1 May 2022 US
Provisional Applications (1)
Number Date Country
61997868 Jun 2014 US
Divisions (1)
Number Date Country
Parent 15354507 Nov 2016 US
Child 16595224 US
Continuations (2)
Number Date Country
Parent 16595224 Oct 2019 US
Child 17575228 US
Parent PCT/US2015/035592 Jun 2015 WO
Child 15354507 US